"Combining two existing prostate cancer therapies could extend the life of men with advanced, high-risk prostate cancer by 37%, according to a study presented at the world’s largest cancer conference. The new findings could change how doctors first approach treatment of prostate cancer.
‘These are the most powerful results I’ve seen from a prostate cancer trial,’ said Nicholas James, the lead author of the abstract presented as the American Society of Clinical Oncology. ‘It’s a once in a career feeling. This is one of the biggest reductions in death I’ve seen in any clinical trial for adult cancers.’
Researchers combined standard hormone therapy with a drug called abiraterone , which is typically used only for cancer patients whose disease has stopped responding to standard hormone therapy. The research was conducted as part of the Stampede trial, an ongoing randomized trial conducted in the UK and Switzerland."